Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $446.
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $446.
